Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Counterpain PXM
- Development stage
- Unknown
- Lead developer
- Taisho Pharmaceutical Indonesia
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Counterpain PXM is a topical analgesic gel developed by Taisho Pharmaceutical Indonesia for the management of musculoskeletal pain and inflammatory conditions. The formulation contains 0.5% piroxicam, a nonsteroidal anti-inflammatory drug (NSAID) that reversibly inhibits cyclooxygenase enzymes (COX-1 and COX-2) to block prostaglandin biosynthesis. This is combined with a blend of counterirritants, including methyl salicylate, menthol, and eugenol, which provide additional analgesic effects by inducing warming and cooling sensations that modulate pain signals. Counterpain PXM is indicated for conditions such as osteoarthritis, tendinitis, sprains, and low back pain, and is currently being evaluated in Phase 3 clinical trials to compare its efficacy and safety against piroxicam-only and diclofenac gels.
- Brand names
- Counterpain PXMCounterpain-PXM
- Other names
- Piroxicam plus Counterirritant gel
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TRPM8 (Transient receptor potential cation channel subfamily M member 8)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Counterpain PXM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Counterpain PXM.